Even though there was no association with the small sample size of NSCLC (n = 21) and HCC (n = 22) (except for CXCR3 in NSCLC that CXCR3 resulted in poor survival rate in patients receiving immunotherapies, p = 0.012, Fig. 4D). This evidence concerns the gene CXCR3 and non-small cell lung carcinoma.